SCHEMBL3264512

SCHEMBL3264512

NC(=O)N(S)c1c(Cl)cccc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
ADRA2A P08913 2/20 0.38
LMNA P02545 2/20 0.38
CYP2D6 P10635 2/20 0.38
HIF1A Q16665 2/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
CYP3A4 P08684 1/20 0.38
HTR1A P08908 1/20 0.38
CYP2C9 P11712 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
MAOA P21397 1/20 0.38
ADRA1D P25100 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C19 P33261 1/20 0.38
ADRA1A P35348 1/20 0.38
DRD3 P35462 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2589475 0.79 TSHR (0.41) ALDH1A1ADRA2ALMNACYP2D6HIF1A
SCHEMBL3917785 0.78 MAPK14 (0.49) ALDH1A1ADRA2ALMNACYP2D6HIF1A
SCHEMBL3265387 0.78 CES2 (0.39) ALDH1A1LMNAKMT2AHSD17B10TSHR
SCHEMBL11655480 0.76 ALDH1A1 (0.37) ALDH1A1LMNAKMT2AMAPTTSHR
SCHEMBL11174076 0.75 MYC (0.36) ALDH1A1KMT2AMEN1CYP3A4HTR2A
SCHEMBL2789991 0.75 CES2 (0.41) ALDH1A1MAPK14CES2CES1PARP1
SCHEMBL12763813 0.75 POLB (0.42) ALDH1A1ADRA2ALMNACYP2D6HIF1A
SCHEMBL11540445 0.75 KMT2A (0.42) ALDH1A1KMT2AMEN1MAPTTSHR
SCHEMBL14053556 0.72 ALDH1A1 (0.40) ALDH1A1KMT2AMEN1HSD17B10TSHR
SCHEMBL11543475 0.72 GABRA1 (0.43) ALDH1A1HIF1AKMT2AMEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed
EP-1899335-A1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PIERRE FABRE MEDICAMENT (FR) 2008-03-19 EP disclosed
WO-2007003611-A1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PIERRE FABRE MEDICAMENT (FR) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 ALDH1A1 3830/4885ADRA2A 4143/4885LMNA 3096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.